KR20100059902A - 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커 - Google Patents

질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커 Download PDF

Info

Publication number
KR20100059902A
KR20100059902A KR1020107006430A KR20107006430A KR20100059902A KR 20100059902 A KR20100059902 A KR 20100059902A KR 1020107006430 A KR1020107006430 A KR 1020107006430A KR 20107006430 A KR20107006430 A KR 20107006430A KR 20100059902 A KR20100059902 A KR 20100059902A
Authority
KR
South Korea
Prior art keywords
disease
sample
protein
patient
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107006430A
Other languages
English (en)
Korean (ko)
Inventor
시르파 잘카넨
마르코 살미
마르쿠 잘카넨
Original Assignee
파론 파머수티컬스 오와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파론 파머수티컬스 오와이 filed Critical 파론 파머수티컬스 오와이
Publication of KR20100059902A publication Critical patent/KR20100059902A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
KR1020107006430A 2007-10-24 2008-10-15 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커 Ceased KR20100059902A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20070795 2007-10-24
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167005473A Division KR20160029869A (ko) 2007-10-24 2008-10-15 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커

Publications (1)

Publication Number Publication Date
KR20100059902A true KR20100059902A (ko) 2010-06-04

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107006430A Ceased KR20100059902A (ko) 2007-10-24 2008-10-15 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커
KR1020167005473A Ceased KR20160029869A (ko) 2007-10-24 2008-10-15 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167005473A Ceased KR20160029869A (ko) 2007-10-24 2008-10-15 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커

Country Status (14)

Country Link
US (1) US20100209942A1 (https=)
EP (2) EP2201376B1 (https=)
JP (2) JP4982610B2 (https=)
KR (2) KR20100059902A (https=)
CA (1) CA2702635A1 (https=)
CY (2) CY1113403T1 (https=)
DK (2) DK2201376T3 (https=)
ES (2) ES2532361T3 (https=)
FI (1) FI20070795A0 (https=)
HR (2) HRP20120743T1 (https=)
PL (2) PL2201376T3 (https=)
PT (2) PT2201376E (https=)
SI (2) SI2201376T1 (https=)
WO (1) WO2009053523A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150118107A (ko) * 2013-02-14 2015-10-21 파론 파머수티컬스 오와이 급성 호흡 곤란 증후군 (ards) 관련 바이오마커를 결정하는 방법, 환자의 ards 의 발달을 모니터링하고 치료하는 방법

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
EP2596134B1 (en) 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012012693A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
WO2013188846A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions
EP2861788B1 (en) 2012-06-15 2018-10-10 Progenity, Inc. Methods of detecting diseases or conditions using circulating diseased cells
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2228970A1 (en) * 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
AU7310496A (en) * 1995-10-13 1997-04-30 Imperial College Of Science, Technology And Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
US20030099608A1 (en) * 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
WO2004084933A1 (en) * 2003-03-28 2004-10-07 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
CN1835962A (zh) * 2003-06-03 2006-09-20 加利福尼亚大学董事会 利用乙酰化二糖治疗疾病的组合物与方法
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150118107A (ko) * 2013-02-14 2015-10-21 파론 파머수티컬스 오와이 급성 호흡 곤란 증후군 (ards) 관련 바이오마커를 결정하는 방법, 환자의 ards 의 발달을 모니터링하고 치료하는 방법

Also Published As

Publication number Publication date
EP2503338A3 (en) 2013-03-13
SI2201376T1 (sl) 2012-09-28
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
PL2503338T3 (pl) 2015-06-30
JP2011501176A (ja) 2011-01-06
EP2503338B1 (en) 2014-12-24
CA2702635A1 (en) 2009-04-30
PT2503338E (pt) 2015-03-05
JP2012159514A (ja) 2012-08-23
SI2503338T1 (sl) 2015-06-30
CY1116089T1 (el) 2017-02-08
FI20070795A0 (fi) 2007-10-24
JP4982610B2 (ja) 2012-07-25
HRP20150181T1 (hr) 2015-06-19
DK2503338T3 (en) 2015-03-09
CY1113403T1 (el) 2016-06-22
US20100209942A1 (en) 2010-08-19
KR20160029869A (ko) 2016-03-15
ES2389751T3 (es) 2012-10-31
EP2503338A2 (en) 2012-09-26
PL2201376T3 (pl) 2013-01-31
WO2009053523A1 (en) 2009-04-30
EP2201376A4 (en) 2011-03-23
EP2201376B1 (en) 2012-08-08
ES2532361T3 (es) 2015-03-26
JP5619810B2 (ja) 2014-11-05
PT2201376E (pt) 2012-08-20
DK2201376T3 (da) 2012-10-15

Similar Documents

Publication Publication Date Title
KR20100059902A (ko) 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커
JP6263474B2 (ja) ヌクレオソームアダクト検出法
CN106461677B (zh) 肺高血压病的检查方法
JP7094700B2 (ja) 喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用
JP6983221B2 (ja) 大腸癌の併用検査
JP2025019061A (ja) 術後有害事象の診断または予後
JP2016513253A (ja) 急性呼吸促迫症候群（ａｒｄｓ）関連バイオマーカーを測定する方法、患者におけるａｒｄｓの進行および治療をモニターする方法
US20130217033A1 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
Bartosik‐Psujek et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
JP2008514209A5 (https=)
Backen et al. ‘Fit-for-purpose’validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use
CN107615071B (zh) 用于包含乐伐替尼和依维莫司的联合疗法的生物标志
US11415584B2 (en) Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug
CN102821780A (zh) 经历经皮冠状动脉介入术的患者中再狭窄的诊断
Xu et al. Longitudinal relationships between serum ferritin and prognosis among severe community-acquired
Siebenhaar et al. Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation
Rafnsson Endothelial dysfunction in atherosclerosis and type 2 diabetes: Clinical and molecular studies of the role of endothelin and arginase
EA049714B1 (ru) Способ триажа с использованием бесклеточных нуклеосомных уровней
HK1255151B (en) Use of cell-free nucleosomes as biomarkers in sputum samples
JP2013504075A5 (https=)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

J301 Trial decision

Free format text: TRIAL NUMBER: 2016101001271; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160229

Effective date: 20170630

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20170630

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2010 7006430

Appeal request date: 20160229

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016101001271

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000